Ms Julie Tibbets > Goodwin > Washington DC, United States > Lawyer Profile
Goodwin Offices
901 NEW YORK AVENUE, NW
WASHINGTON DC 20001
DISTRICT OF COLUMBIA
United States
- Firm Profile
- Go to...
Ms Julie Tibbets
Position
Partner
Career
Julie Tibbets is a partner in Goodwin’s Technology and Life Sciences group and a member of its FDA practice.
Ms. Tibbets focuses her practice on FDA-regulated product development, marketing and corporate communications as well as the intersection of each of those with corporate strategy and securities disclosure obligations. Her product areas of focus include biologics, drugs, medical devices, in vitro diagnostics, lab-developed tests, as well as digital health tools and apps. Ms. Tibbets advises clients on product development strategy, interactions with the FDA, clinical trial documentation, adverse event reporting, commercial strategy, product labeling and advertising. She also leads the regulatory due diligence reviews of FDA-regulated M&A or investment targets, potential collaborators and licensees, and guides the regulatory disclosures of FDA-regulated entities in their initial public offerings. Ms. Tibbets also works closely with the Food + Healthy Living practice team at Goodwin on the intersection of food, supplement and cosmetic regulation with FDA’s drug and device authorities.
Education
J.D., 2004 University of North Carolina, Chapel Hill B.A., 2001 Purdue University (Highest Honors)
Top Tier Firm Rankings
- Finance > Financial services regulation
- Industry focus > Cannabis
- Intellectual property > Patents: licensing
- Real estate > Real estate investment trusts (REITs)
- Media, technology and telecoms > Technology transactions
- M&A/corporate and commercial > Venture capital and emerging companies
Firm Rankings
- Finance > Capital markets: equity offerings
- Industry focus > Education
- Labor and employment > ERISA litigation
- Finance > Fintech
- Healthcare > Life sciences
- Dispute resolution > M&A litigation: defense
- M&A/corporate and commercial > M&A: middle-market ($500m-999m)
- Investment fund formation and management > Mutual/registered/exchange-traded funds
- Dispute resolution > Securities litigation: defense
- Finance > Capital markets: debt offerings
- International Trade > CFIUS
- M&A/corporate and commercial > Corporate governance
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Dispute resolution > E-discovery
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Dispute resolution > Financial services litigation
- Antitrust > Merger control
- Intellectual property > Patents: litigation (full coverage)
- Investment fund formation and management > Private equity funds (including venture capital)
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Real estate > Real estate
- M&A/corporate and commercial > Shareholder activism
- Intellectual property > Trade secrets (litigation and non-contentious matters)
- Tax > US taxes: non-contentious
- Labor and employment > Workplace and employment counseling
- Labor and employment > Employee benefits, executive compensation and retirement plans: design
- Dispute resolution > Leading trial lawyers
- M&A/corporate and commercial > Private equity buyouts: large deals ($500m+)
- Healthcare > Service providers
- International Trade > Customs, export controls and economic sanctions
- Dispute resolution > Leading trial lawyers
- Finance > Restructuring (including bankruptcy): corporate
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Finance > Commercial lending
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)